Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 11/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.42 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7087907 | 0.85 | PTGS2 (0.61) | PTGS2PTGS1GRIA4DRD1 | |
| SCHEMBL7084451 | 0.84 | FFAR1 (0.44) | PTGS2CA1CA2PTGS1DRD1 | |
| SCHEMBL7085155 | 0.80 | PTGS2 (0.48) | PTGS2HTR2AHTR2CPTGS1 | |
| SCHEMBL7089387 | 0.74 | PTGS2 (0.48) | PTGS2PTGS1 | |
| SCHEMBL9206986 | 0.74 | PTGS2 (0.73) | PTGS2PTGS1DRD1 | |
| SCHEMBL7085561 | 0.72 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL7090583 | 0.72 | PTGS2 (0.53) | PTGS2 | |
| SCHEMBL27688803 | 0.72 | HTR2A (0.73) | HTR2AHTR2CCA1CA2 | |
| SCHEMBL7084454 | 0.71 | PTGS2 (0.59) | PTGS2CA1CA2PTGS1DRD1 | |
| SCHEMBL8604252 | 0.71 | PTGS2 (0.59) | PTGS2PTGS1DRD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | G.D. SEARLE & CO. | 2003-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030050330-A1 | 4,5-subtstituted imdazolyl compounds for the treatment of inflammation | AHR, HACL2, IRAK2 | PTGS2 122/4885HTR2A 605/4885HTR2C 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.